SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a massive, unsolicited $56 billion bid to acquire eBay, a move that has ignited intense debate over potential stock dilution versus the strategic ambition to build an e-commerce rival to Amazon. The community remains deeply polarized, with bulls viewing the play as a bold, long-term transformational move, while vocal bears and skeptics are heavily criticizing the CEO's confrontational media presence and the logistical hurdles of the proposed financing.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing intense investor interest driven by a massive short squeeze setup, characterized by high borrowing costs and low share availability. The community is focused on the upcoming earnings report as a major catalyst for momentum, with many bulls actively discouraging selling and urging a long-term hold to maximize pressure on short sellers.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies is experiencing extreme volatility driven by a prospectus filing that registers a large volume of existing Class B shares for potential resale, which the community is debating as either a standard liquidity event or a sign of an impending supply overhang. Investors are actively discussing the technical merits of the company's photonic quantum approach, while many express mixed sentiment over the stock's speculative nature and the rapid price fluctuations following the registration news.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors aggressively buy into a structural memory supercycle, with community members highlighting that AI infrastructure demand for DRAM and HBM is decoupling the stock from traditional cyclical patterns. Bullish sentiment remains dominant as market participants point to supply shortages and major hyperscale partnerships as the primary drivers, with many actively discussing the potential for a massive rerating as the stock approaches new highs.

Elong Power Holding Ltd. engages in the research and development, manufacturing, sales and service of high-power lithium-ion batteries for electric vehicles and construction machinery, as well as large-capacity, long-cycle lithium-ion batteries for energy storage systems. The company was founded on August 18, 2023 and is headquartered in Ganzhou, China.

Elong Power Holding Ltd. - Ordinary Shares - Class A

Elong Power Holding Limited

Elong Power Holding Limited (ELPW) is experiencing high-volume volatility and active short-squeeze speculation, with the community closely tracking the ticker alongside other low-float, China-based small caps. Retail traders are intensely focused on key price levels and resistance breakouts while debating the sustainability of the move versus potential downside risk.

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Cns Pharmaceuticals Inc

Cns Pharmaceuticals is experiencing intense volatility and volume as investors react to a private placement financing announcement, fueling intense community debates about potential squeezes versus long-term dilution concerns. Retail traders are closely monitoring the stock's tight float and rapid price swings, with active discussions centered on technical breakout levels and the company's shifting strategic focus.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Clene Inc. is currently a focal point for investors as the community anticipates critical upcoming data regarding biomarker analysis and potential FDA accelerated approval pathways for its ALS candidate, CNM-Au8. Discussion is heavily focused on the company's regulatory roadmap, the impact of recent insider selling, and the broader context of how emerging biomarker evidence could influence the stock's long-term valuation.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

HTCO is experiencing significant volatility driven by heavy short interest and a low-float structure, with community discussions largely centered on aggressive short squeeze potential and speculative trading dynamics. Investors are debating the sustainability of the price action, frequently drawing parallels to past momentum plays while others warn of the risks associated with rapid, news-sparse price swings.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following an unsolicited takeover proposal from GameStop, which has fueled intense community debate over the feasibility of the deal and the potential for a massive acquisition strategy. Market participants are actively scrutinizing the financing requirements and the viability of a cash-and-stock offer that significantly exceeds GameStop's current market valuation.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as investors rally behind the upcoming April 30 PDUFA date for the label expansion of Auvelity into Alzheimer's disease agitation. The community is heavily focused on the stock's multi-year growth trajectory, institutional accumulation, and the potential for Auvelity to become a dominant CNS blockbuster, with many discussing its prospects as a prime acquisition target for big pharma.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is WisdomTree U.S. SmallCap ETF (EES) a Strong ETF Right Now?

Should WisdomTree U.S. SmallCap ETF (EES) Be on Your Investing Radar?

<ul class="summary-bullets"><li>The&nbsp;company&nbsp;opened nine new stores and closed five stores during fiscal 2025.</li><li>JILL said that for the first quarter of fiscal 2026, the company expects its net sales to decline 5% to 7% compared to fiscal 2025.</li><li>Jefferies lowered the firm's price target on J.Jill to $14 from $18 and kept a ‘Buy’ rating on the shares.</li></ul><p>Shares of J. Jill (JILL) slumped 26% on Tuesday after it reported a 3.1% decline in its fourth quarter net sales.&nbsp;</p><p>Net sales for the fourth quarter of fiscal 2025 decreased 3.1% to $138.4 million compared to $142.8 million for the fourth quarter of fiscal 2024, it said. Analysts expected revenue of $135.5 million as per data from Stocktwits.&nbsp;</p><p>JILL reported adjusted net loss per diluted share in the fourth quarter of fiscal 2025 at $0.02 compared to adjusted net income per diluted share of $0.32 in the fourth quarter of fiscal 2024.</p><p>The company opened nine new stores and closed five stores during fiscal 2025, ending the year with 256 stores compared to 252 stores at the end of fiscal 2024.</p><h2 class="st-heading-2">Analyst Rationale</h2><p>Jefferies lowered the firm's price target on J.Jill to $14 from $18 and kept a ‘Buy’ rating on the shares following the company’s earnings report. The analyst told investors in a note that J.Jill delivered Q4 results "above a low bar," but "more importantly" FY26 guidance came in well below Street expectations, driven by cautious demand assumptions and incremental tariff headwinds.</p><p>BTIG analyst Janine Stichter lowered the firm's price target on J.Jill to $18 from $21 and kept a ‘Buy’ rating on the shares.</p><h2 class="st-heading-2">Outlook</h2><p>JILL said that for the first quarter of fiscal 2026, the company expects its net sales to decline 5% to 7% compared to fiscal 2025. Analysts expected revenue for the quarter at $155.65 million, as per Stocktwits.&nbsp;</p><p>For the full year of fiscal 2026, the company expects net sales to be flat to down 2% compared to fiscal 2025.</p><p>JILL said that the outlook assumes an average 20% reciprocal tariff rate on applicable inventory received prior to February 28, 2026, an average 10% reciprocal tariff rate on applicable inventory received after February 28, 2026 through the first quarter of fiscal 2026, and an average 15% reciprocal tariff rate thereafter.&nbsp;</p><h2 class="st-heading-2">Retail Reaction</h2><p>Retail sentiment around JILL trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;</p><p>Shares in the company are down 19% so far in 2026.&nbsp;</p><p>&nbsp;</p>

BTIG analyst Janine Stichter lowered the firm's price target on J.Jill to $18 from $21 and kept a ‘Buy’ rating on the shares.

J. Jill Stock Slumps 26% Today – Why Such A Selloff?

JILL’s net sales for the fourth quarter of fiscal 2025 decreased 3.1% to $138.4 million year-over-year. 

Equity

JILL’s net sales for the fourth quarter of fiscal 2025 decreased 3.1% to $138.4 million year-over-year. 


<ul class="summary-bullets"><li>The revenue fell well short of analyst estimates of $144.95 million, according to data from Fiscal.ai.&nbsp;</li><li>The company said that its gross margin for Q4 was at 13.4%, compared to gross margin of 15.3% from year-ago.&nbsp;</li><li>The company said it expects FY 2026 revenue of $500 million to $550 million. However, it fell way short of Wall Street expectations of $625.65 million.&nbsp;</li></ul><p>FreightCar America shares slumped 19% during extended hours of trading on Monday as it reported a decline in its fourth quarter revenue.&nbsp;</p><p>The company said its revenues in Q4 came at $125.6 million,&nbsp;lower than $137.7 million in the fourth quarter of 2024, despite railcar deliveries of 1,172 units compared to 1,019 units in the prior year period.&nbsp;</p><p>The revenue fell well short of analyst estimates of $144.95 million, according to data from Fiscal.ai.&nbsp;</p><h2 class="st-heading-2">Q4 Snapshot</h2><p>The company posted a fall in its profit in Q4. It reported adjusted net income of $4.9 million, or $0.16 per share, compared to $0.21 per share from the year-ago quarter. RAIL also missed profit expectations of $0.19 per share, as per Fiscal.ai.&nbsp;</p><p>“In 2025, FreightCar America executed with discipline amid a challenging industry environment, delivering revenue in line with our expectations while producing exceptional profitability,” said Nick Randall, President and Chief Executive Officer of FreightCar America.</p><p>The company said that its gross margin was at 13.4% with gross profit of $16.8 million, compared to gross margin of 15.3% with gross profit of $21.0 million in the fourth quarter of 2024.&nbsp;</p><h2 class="st-heading-2">Outlook</h2><p>The company said it expects FY 2026 revenue of $500 million to $550 million. However, it fell way short of Wall Street expectations of $625.65 million.&nbsp;</p><p>“As we enter 2026, we remain focused on converting backlog into profitable deliveries while continuing to invest for growth,” Randall said.&nbsp;</p><p>“Looking ahead to 2026, our guidance reflects ongoing industry uncertainty while reinforcing our confidence in the underlying strength and resilience of the business,” said Mike Riordan, Chief Financial Officer of FreightCar America.&nbsp;</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>Retail sentiment around RAIL trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;</p><p>Shares in the company have fallen nearly 11% so far in 2026.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Freightcar Americs said its revenues in Q4 came at $125.6 million, lower than $137.7 million in the fourth quarter of 2024. 

FreightCar America Slumps 21% As Q4 Results And FY26 Disappoints Investors

The company said its revenues in Q4 came at $125.6 million, lower than $137.7 million in the fourth quarter of 2024, despite railcar deliveries of 1,172 units compared to 1,019 units in the prior year period. 

<ul class="summary-bullets"><li>Seres said the pause follows the completion of study site evaluation and qualification work with its contract research organization.</li><li>The company said following the pause in additional investment into the SER-155 Phase 2 study, it will shift its operational focus to high-value earlier-stage pipeline programs.</li><li>Seres noted that its cost-cutting measures are expected to extend its cash runway into the third quarter of 2026.</li></ul><p>Seres Therapeutics Inc. (MCRB) shares fell more than 21% in Thursday’s pre-market trade after the company announced that it is pausing a planned Phase 2 study, while reducing the headcount by 30% to extend its cash runway.</p><p>Seres stated that it has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the U.S. Food and Drug Administration (FDA).</p><p>“As we pursue earlier stage programs with the greatest opportunity, such as those targeting inflammatory bowel disease (IBD), we are exploring collaborations to provide additional capital to the company,” said Thomas DesRosier and Marella Thorell, co-CEOs of Seres.</p><h2 class="st-heading-2">Why Did Seres Pause The Study?</h2><p>Seres said the pause follows the completion of study site evaluation and qualification work with its contract research organization, adding that the Phase 2 study drug substance has already been manufactured.</p><p>The company said that following the pause in additional investment into the SER-155 Phase 2 study, it will shift its operational focus to high-value earlier-stage pipeline programs. At the same time, it will continue to seek funding for the Phase 2 study, Seres said.</p><h2 class="st-heading-2">Extending Cash Runway</h2><p>Seres noted that its cost-cutting measures, including workforce reductions, are expected to extend its cash runway into the third quarter (Q3) of 2026.</p><p>The company said that this will help in supporting the continued development of its programs for inflammatory and immune-related diseases, while also giving it additional time to secure funding for the SER-155 Phase 2 study.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/MCRB">Seres Therapeutics</a> trended in the ‘bullish’ territory at the time of writing, with message volumes at ‘high’ levels.</p><p>One user on Stocktwits said that Seres’ announcement confirms that “there is no one interested to partner” with the company.</p><p><stembedurl>https://stocktwits.com/Kenny1207/message/644771398</stembedurl></p><p><a href="https://stocktwits.com/symbol/MCRB">MCRB stock</a> is down 51% year-to-date and 75% over the past 12 months.</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/samsung-ships-world-first-commercial-hbm4-memory-module-ai-computing/cZRTlXNR4ra"><strong>Samsung Ships First Commercial HBM4 Memory Module, Nvidia’s Vera Rubin Expected To Use It: SSNLF Stock Soars 55%</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Seres Therapeutics biotechnology company building, Cambridge, Massachusetts, USA

MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30%

The company said that it will continue to seek funding for the SER-155 Phase 2 study.

Current Price	$63.94
Prev Close	$63.99
Open	$63.50
Dividend Yield	N/A
50-Day Moving Average	$59.84
Beta	N/A
Avg. Volume	13,521.62
PE Ratio	N/A

52-Week High	$64.05
52-Week Low	$47.13
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

EES
WisdomTree Trust - WisdomTree U.S. SmallCap Fund

Feed

News

Sentiment

Fundamentals

Info

Latest EES News

EESWisdomTree Trust - WisdomTree U.S. SmallCap Fund